How many drugs treat Hypokalemia Prevention?

Drug Landscape tracks 9 marketed treatments for Hypokalemia Prevention (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/hypokalemia-prevention.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Hypokalemia Prevention — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hypokalemia Prevention (disease) competitive landscape: 9 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

9 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Hypokalemia Prevention, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Midamor	AMILORIDE	Padagis Us	Potassium-sparing Diuretic	Amiloride-sensitive sodium channel, ENaC	1981-01-01
Sodium Lactate In Plastic Container	SODIUM LACTATE	Pfizer	sodium lactate		1971-01-01
Potassium Acetate	Potassium Acetate	Pfizer	potassium acetate		1971-01-01
Plegisol In Plastic Container	CALCIUM CHLORIDE	Pfizer	calcium chloride		1971-01-01
Micro-K 10	POTASSIUM CHLORIDE	Nesher Pharms	potassium chloride	Carbonic anhydrase 4	1965-01-01
Aldactone	spironolactone	Generic (originally Searle/Pfizer)	Aldosterone Antagonist [EPC]	Cytochrome P450 2C19, Multidrug and toxin extrusion protein 1, Nuclear receptor subfamily 1 group I member 2	1960-01-01
Spironolacton	Spironolacton	ACS Biomarker		Cytochrome P450 2C19, Multidrug and toxin extrusion protein 1, Nuclear receptor subfamily 1 group I member 2
Aspart	Aspart	Emory University	Insulin Analog [EPC]	Aminoacylase-1, Argininosuccinate synthase, Aspartate aminotransferase, cytoplasmic
spirolactone	spirolactone	Second Xiangya Hospital of Central South University		Cytochrome P450 2C19, Multidrug and toxin extrusion protein 1, Nuclear receptor subfamily 1 group I member 2

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 3 drugs in Hypokalemia Prevention
· 3 drugs in Hypokalemia Prevention
Emory University · 1 drug in Hypokalemia Prevention
Generic (originally Searle/Pfizer) · 1 drug in Hypokalemia Prevention
Nesher Pharms · 1 drug in Hypokalemia Prevention
Padagis Us · 1 drug in Hypokalemia Prevention
Second Xiangya Hospital of Central South University · 1 drug in Hypokalemia Prevention
ACS Biomarker · 1 drug in Hypokalemia Prevention

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Hypokalemia Prevention:

Cite this brief

Drug Landscape (2026). Hypokalemia Prevention — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/hypokalemia-prevention. Accessed 2026-06-10.

Hypokalemia Prevention full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing